Exchange: NASDAQ·Updated 07:39 PM EDT
News
all
press releases
This Small-Cap Biotech Just Soared Over 160% — What Is The Novo Nordisk Connection?
Veru will evaluate enobosarm alongside Novo Nordisk’s Wegovy in the Phase 2b PLATEAU trial in older adults with obesity.
Stocktwits
More News
Earnings call transcript: Veru Inc Q2 2026 shows improved financials
Press Releases
Veru (VERU) Q1 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
A Look Ahead: Veru's Earnings Forecast
read more...
Benzinga
Top Wall Street Forecasters Revamp Veru Expectations Ahead Of Q4 Earnings
read more...
Benzinga
Veru Announces Novel Modified-Release Oral Formulation for Enobosarm
VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.
Zacks

Advertisement|Remove ads.